Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases

OBSIDIAN – real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis

(2021) Ilaria Maccora et al.   RHEUMATOLOGY

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability

(2021) Xin Zhou et al.   Drug Design Development and Therapy

Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group

(2021) Fatma Gül Demirkan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis

(2021) Chiara Trincianti et al.   Arthritis & Rheumatology

SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis

(2020) Antonella Di Cesare et al.   Dermatologic Therapy

Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases

(2020) Cosimo Bruni et al.   CLINICAL RHEUMATOLOGY

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa

(2020) Federica Ricceri et al.   Dermatologic Therapy

Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review

(2020) Anja St Clair-Jones et al.   Rheumatology and Therapy

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity

(2020) Tom W. J. Huizinga et al.   Rheumatology and Therapy

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis

(2019) Sarah Ringold et al.   ARTHRITIS CARE & RESEARCH

Juvenile idiopathic arthritis-associated uveitis

(2019) Ethan S. Sen et al.   CLINICAL IMMUNOLOGY

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

(2018) Gerd Horneff et al.   JOURNAL OF PEDIATRICS

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

(2018) Sizheng Zhao et al.   Current Rheumatology Reports

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

(2017) Athimalaipet V. Ramanan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

(2016) Jyoti Velayudhan et al.   BIODRUGS

Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry

(2012) M. E. ZANNIN et al.   JOURNAL OF RHEUMATOLOGY